Armata Pharmaceuticals Inc
$ 10.63
-10.37%
25 Feb - close price
- Market Cap 387,005,000 USD
- Current Price $ 10.63
- High / Low $ 12.22 / 10.05
- Stock P/E N/A
- Book Value -2.64
- EPS -1.66
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -34.39 %
- 52 Week High 12.23
- 52 Week Low 0.90
About
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment of antibiotic-resistant infections worldwide. The company is headquartered in Marina del Rey, California.
Analyst Target Price
$15.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-12 | 2025-05-05 | 2025-03-19 | 2024-11-12 | 2024-08-13 | 2024-05-07 | 2024-03-21 | 2023-11-14 | 2023-08-14 | 2023-05-11 | 2023-03-16 |
| Reported EPS | -0.74 | -0.45 | -0.1973 | -0.2317 | -0.15 | 0.25 | -0.69 | -0.55 | -0.75 | -0.1 | -0.4 | -0.29 |
| Estimated EPS | -0.5 | -0.39 | -0.38 | -0.35 | -0.28 | -0.44 | -0.31 | -0.35 | -0.31 | -0.37 | -0.32 | -0.28 |
| Surprise | -0.24 | -0.06 | 0.1827 | 0.1183 | 0.13 | 0.69 | -0.38 | -0.2 | -0.44 | 0.27 | -0.08 | -0.01 |
| Surprise Percentage | -48% | -15.3846% | 48.0789% | 33.8% | 46.4286% | 156.8182% | -122.5806% | -57.1429% | -141.9355% | 72.973% | -25% | -3.5714% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARMP
2026-02-23 12:07:18
Armata Pharmaceuticals has been granted Qualified Infectious Disease Product (QIDP) designation by the FDA. This designation is typically given to antibacterial or antifungal drugs intended to treat serious or life-threatening infections, potentially accelerating the development and review process for the company's relevant product.
2026-02-23 12:07:17
Armata Pharmaceuticals (ARMP) has been granted Qualified Infectious Disease Product (QIDP) status by the FDA for its AP-SA02 phage therapy, intended for complicated S. aureus bacteremia. This designation provides five additional years of market exclusivity and potential accelerated regulatory pathways, supporting the company's plan to advance AP-SA02 into a Phase 3 trial in the second half of 2026. Despite weak financial performance, this regulatory milestone strengthens Armata's competitive position in developing novel bacteriophage treatments for drug-resistant infections.
2026-02-23 12:07:17
Armata Pharmaceuticals has received FDA Qualified Infectious Disease Product (QIDP) designation for its IV multi-phage candidate, AP-SA02. This designation grants five years of market exclusivity under the GAIN Act and makes AP-SA02 eligible for Fast Track status, potentially accelerating its review for complicated S. aureus bacteremia treatment. Armata plans to request Fast Track and initiate a Phase 3 study in the latter half of 2026.
2026-02-23 11:59:40
Armata Pharmaceuticals has been granted Qualified Infectious Disease Product (QIDP) designation by the FDA for its investigational drug AP-SA02. This designation applies to the intravenous use of AP-SA02 for the adjunct treatment of complicated bacteremia caused by Staphylococcus aureus, including both MSSA and MRSA strains. The QIDP status provides incentives such as five years of market exclusivity and eligibility for Fast Track status, aiming to accelerate the development of this bacteriophage-based therapy for antibiotic-resistant infections.
2026-02-17 00:27:34
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) saw a significant increase in short interest in January, rising 23.8% to 274,891 shares, representing 4.9% of shares outstanding. The company's stock traded down 1.1% to $8.15, with a market capitalization of $296.7 million. Analysts maintain a "Buy" rating with an average price target of $12.00, and institutional investors have adjusted their holdings.
2026-02-03 12:08:15
This article highlights 12 healthcare stocks experiencing significant price movements in Tuesday's pre-market session. It lists top gainers including Liminatus Pharma, CDT Equity, and DaVita, noting their percentage increases and market capitalizations. Conversely, it identifies key losers such as Armata Pharmaceuticals, Avanos Medical, and Kairos Pharma, detailing their respective percentage decreases and market values.
